AstraZeneca Drug Pipeline

AstraZeneca maintains a substantial portfolio of clinical programs, with 360 active trials out of 2034 registered since 2008. These active trials span all phases of development: 107 in Phase 1, 116 in Phase 2, 170 in Phase 3, and 14 in Phase 4. The company’s research activity extends across 15 therapeutic areas, with a pronounced concentration in oncology, which accounts for 79% of active programs (285 trials). Within oncology, the leading indications by active trial count are non-small cell lung cancer (NSCLC) with 57 active trials including 27 in Phase 3, breast cancer with 29 active trials including 19 in Phase 3, and advanced solid tumors with 28 active trials including 9 in Phase 3. Other areas of focus include respiratory (24 active trials), immunology (15 active trials), renal (9 active trials), metabolic (7 active trials), and cardiovascular (3 active trials). The high proportion of programs in Phase 3, particularly within oncology, suggests a pipeline weighted toward near-term milestones.